Syncom Formulations sets record date for ₹0.10 final dividend

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Syncom Formulations fixes September 23, 2026, as the record date for its final dividend
  • The proposed payout is ₹0.10 per equity share of face value ₹1 for FY26
  • Shareholder approval at the AGM on September 30, 2026, is required for the payout
  • Dividend waivers must be submitted by September 26, 2026
powered bylight_fuzz_icon
51258494

*this image is generated using AI for illustrative purposes only.

Syncom Formulations has fixed September 23, 2026, as the record date for determining shareholder eligibility for its final dividend for FY26. The company proposes a payout of ₹0.10 per equity share of face value ₹1 each.

The dividend declaration is subject to approval by members at the company’s 38th Annual General Meeting (AGM). The AGM is scheduled to be held on September 30, 2026, at 2:00 pm via video conferencing or other audio-visual means.

Dividend Details

The final dividend relates to the financial year ended March 31, 2026. Shareholders on record as of September 23, 2026, will be eligible to receive the payout if approved by shareholders.

Metric Detail
Dividend Rate 10%
Amount Per Share ₹0.10
Face Value ₹1
Record Date September 23, 2026
Financial Year FY26

Waiver Process

Shareholders who wish to voluntarily waive their entitlement to the dividend, either in full or in part, must submit a duly filled and signed Dividend Waiver Form. The form is available on the company’s website.

Completed forms must be sent to the company or its Registrar and Transfer Agent (RTA) on or before September 26, 2026. This deadline ensures the waiver is processed before the dividend payment date.

Regulatory Disclosure

The announcement was made pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Section 91 of the Companies Act, 2013.

Historical Stock Returns for Syncom Formulations

1 Day5 Days1 Month6 Months1 Year5 Years
+6.39%+3.74%+31.27%+72.84%+11.00%+146.67%

How does the proposed ₹0.10 dividend per share compare to Syncom Formulations' payout history and peer averages in the pharmaceutical sector?

What is the expected impact of this dividend payout on the company's retained earnings and future capital allocation strategies for FY27?

Will the 38th AGM address any strategic initiatives or operational updates alongside the dividend approval?

Syncom Formulations AGM to approve Rahul Bankda as MD, Rinki Bankda as WTD

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Syncom Formulations schedules 38th AGM for September 30, 2026
  • Rahul Bankda appointed MD; Rinki Bankda appointed WTD
  • Final dividend of ₹0.10 per share proposed for FY26
  • CFO Ankur Bankda's salary increased to ₹3.5 lakh per month
powered bylight_fuzz_icon
50338063

*this image is generated using AI for illustrative purposes only.

Syncom Formulations has scheduled its 38th Annual General Meeting (AGM) for September 30, 2026. The meeting will commence at 2:00 pm via Video Conferencing or Other Audio Visual Means. Key agenda items include the appointment of Mr. Rahul Vijay Bankda as Managing Director and Mrs. Rinki Ankit Bankda as Whole-Time Director.

The company submitted the notice alongside its 38th Annual Report for FY26. The filing includes the balance sheet, profit and loss statement, cash flow statement, and statement of changes in equity. Syncom achieved total revenue of ₹51,753.91 crore and Profit Before Tax of ₹10,052.51 crore for the financial year ended March 31, 2026.

Board Appointments

Shareholders will vote on several key managerial appointments:

  • Managing Director: Mr. Rahul Vijay Bankda will be appointed as Managing Director for three years, effective August 12, 2026. His proposed remuneration is up to ₹1.2 crore per annum with a 10% annual increment.
  • Whole-Time Director: Mrs. Rinki Ankit Bankda will be appointed as Whole-Time Director for three years, effective August 12, 2026. Her proposed remuneration is up to ₹60 lakh per annum with a 10% annual increment.
  • CFO Remuneration: The remuneration of Chief Financial Officer Mr. Ankur Vijay Bankda will be increased from ₹2.25 lakh per month to ₹3.50 lakh per month, effective October 1, 2026.
  • Independent Director: Mrs. Ruchi Jindal will be re-appointed as an Independent Director for a second term of five years, effective June 28, 2027.

Dividend Declaration

The Board proposes a final dividend of 10%, i.e., ₹0.10 per equity share of face value ₹1 each, for FY26. The record date for determining eligible shareholders is September 23, 2026. Payment is scheduled before October 30, 2026.

Regulatory Compliance

The submission adheres to Regulation 34(1) of the SEBI (LODR) Regulations, 2015. Documents were filed on September 7, 2026, with both the Bombay Stock Exchange and the National Stock Exchange of India. The annual report also contains the Board’s Report, Corporate Governance Report, Business Responsibility and Sustainability Report (BRSR), and the Auditors’ Report.

Vaishali Agrawal, Company Secretary and Compliance Officer, signed the submission digitally.

Historical Stock Returns for Syncom Formulations

1 Day5 Days1 Month6 Months1 Year5 Years
+6.39%+3.74%+31.27%+72.84%+11.00%+146.67%

How might the appointment of Rahul Vijay Bankda as Managing Director influence Syncom Formulations' strategic direction and operational efficiency in the coming fiscal years?

Given the proposed 10% dividend payout, what does this signal about management's confidence in future cash flows and growth opportunities versus returning capital to shareholders?

What impact could the 55% increase in the CFO's monthly remuneration have on the company's overall compensation structure and investor perception of executive pay alignment?

More News on Syncom Formulations

1 Year Returns:+11.00%